A 16q22.1 variant confers susceptibility to colorectal cancer as a distal regulator of ZFP90
Chenyang Yu(Sichuan University), Jing‐Yuan Fang(Shanghai Institute of Hematology), Penglei Jiang(Zhejiang University), Ji‐Xuan Han(Shanghai Jiao Tong University), Fangfang Guo(Southern Medical University), Wan Du(University of Michigan), Haoyan Chen(Shanghai Jiao Tong University), Jia‐Yin Tang(Southwest Jiaotong University), Jinxian Chen(Nanjing Agricultural University), Tingting Yan(Nanjing Drum Tower Hospital), Dan Ma(Aston University), Xiaoqiang Zhu(Shanghai Institute of Hematology), Chaoqin Shen(Sun Yat-sen University), Yuanhong Xie(Shanghai Jiao Tong University), Xianglong Tian(Shanghai Eighth People Hospital), Weiping Zou(University of Michigan), Qiang Liu(Shanghai Jiao Tong University), Junfang Zhang(Tongji University), Ming Zhong(Sun Yat-sen University), Yingxuan Chen(Renji Hospital), Ye Hu(Arizona State University), Danfeng Sun, Jie Hong(Shanghai Jiao Tong University)
Cited by 22
Related Papers
Comprehensive review of targeted therapy for colorectal cancer
|Signal Transduction and Targeted Therapy|2020|1.7k
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
|Current Opinion in Immunology|2013|740
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
|Journal of Clinical Investigation|2018|598
m6A-dependent glycolysis enhances colorectal cancer progression
|Molecular Cancer|2020|465